DPH Dechra Pharmaceuticals Plc

TIDMDPH

RNS Number : 7344P

Dechra Pharmaceuticals PLC

21 October 2021

Thursday, 21 October 2021

Dechra(R) Pharmaceuticals PLC

(Dechra, Group, Company)

Annual General Meeting

Trading update

The Board of Dechra issues the following statement prior to the Annual General Meeting (AGM) which will take place at the Company's offices at 6 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, CW9 7UA at 9.30 am today, Thursday 21 October 2021:

Trading in the first quarter of the financial year was strong, especially in the US as we continued to outperform the sector and benefit from strong growth in the Companion Animal market. Although trading is currently encouraging, it remains too early in the year to extrapolate this performance across the full year.

No other new trading updates are to be made at the AGM today.

Dechra will announce its interim results for the six month period to 31 December 2021 on 21 February 2022.

 
 
   Enquiries: 
 Dechra Pharmaceuticals PLC 
 Ian Page, Chief Executive Officer         Office: +44 (0) 1606 814 
                                            730 
 Paul Sandland, Chief Financial Officer    Office: +44 (0) 1606 814 
  e-mail: corporate.enquiries@dechra.com    730 
 
 TooleyStreet Communications Ltd 
 Fiona Tooley, Director                    Mobile: +44 (0) 7785 703 
  e-mail: fiona@tooleystreet.com            523 
                                            Office: +44 (0) 121 309 
                                            0099 
 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture, marketing, and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.

For more information, please visit: www.dechra.com

Stock Code: Full Listing (Pharmaceuticals): DPH

LEI: 213800J4UVB5OWG8VX82

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

Forward Looking Statement

This document may contain certain forward-looking statements. The forward-looking statements reflect the knowledge and information available to the Company during the preparation and up to the publication of this document. By their very nature, these statements depend upon circumstances and relate to events that may occur in the future thereby involve a degree of uncertainty. Therefore, nothing in this document should be construed as a profit forecast by the Company.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TSTPPGAWUUPGGMU

(END) Dow Jones Newswires

October 21, 2021 02:00 ET (06:00 GMT)

Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Mar 2024 a Apr 2024

Grafico Azioni Dechra Pharmaceuticals (LSE:DPH)
Storico
Da Apr 2023 a Apr 2024